Advertisement

Topics

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT

13:32 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead’s second-generation investigational medicine for the ...

Other Sources for this Article

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

NEXT ARTICLE

More From BioPortfolio on "Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...